Anti-pandemic H1N1 influenza vaccine — Competitive Intelligence Brief

Anti-pandemic H1N1 influenza vaccine (Anti-pandemic H1N1 influenza vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: inactivated influenza vaccine. Area: Immunology.

marketed inactivated influenza vaccine Immunology Biologic

Target snapshot

Anti-pandemic H1N1 influenza vaccine (Anti-pandemic H1N1 influenza vaccine) — University of Sao Paulo. The vaccine stimulates the immune system to produce antibodies and cellular immunity against H1N1 influenza virus antigens.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Anti-pandemic H1N1 influenza vaccine TARGET	Anti-pandemic H1N1 influenza vaccine	University of Sao Paulo	marketed	inactivated influenza vaccine
Seasonal trivalent vaccine	Seasonal trivalent vaccine	Sinovac Biotech Co., Ltd	marketed	Inactivated influenza vaccine
SP Shz TIV	SP Shz TIV	Sanofi	marketed	Inactivated influenza vaccine
Fluzone® (IM)	Fluzone® (IM)	National Institute of Allergy and Infectious Diseases (NIAID)	marketed	inactivated influenza vaccine
Standard IIV4	Standard IIV4	Marshfield Clinic Research Foundation	marketed	Inactivated influenza vaccine
trivalent seasonal influenza vaccine	trivalent seasonal influenza vaccine	Sinovac Biotech Co., Ltd	marketed	inactivated influenza vaccine
adjuvanted Arepanrix	adjuvanted Arepanrix	University of British Columbia	marketed	Adjuvanted inactivated influenza vaccine	H1N1 influenza virus hemagglutinin and neuraminidase antigens

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (inactivated influenza vaccine class)

1. Seqirus · 3 drugs in this class
2. Center for Disease Prevention and Control of Beijing Military Region · 2 drugs in this class
3. Sanofi Pasteur, a Sanofi Company · 2 drugs in this class
4. Sinovac Biotech Co., Ltd · 2 drugs in this class
5. La Jolla Institute for Immunology · 1 drug in this class
6. Mount Sinai Hospital, Canada · 1 drug in this class
7. National Institute of Allergy and Infectious Diseases (NIAID) · 1 drug in this class
8. University of Sao Paulo · 1 drug in this class
9. GlaxoSmithKline · 1 drug in this class
10. University of Witwatersrand, South Africa · 1 drug in this class